ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.305,57
-0,34%
S&P 500
5.304,72
0,70%
US Dollar vs BRL
5,13862
0,00%
Bitcoin
68.808,75
-0,66%
Brent Oil
81,965
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Annexon Inc (ANNX)

  7. Annexon Inc (ANNX) Notícias

ANNX

Annexon (ANNX)

Annexon Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ANNX
DataHoraFonteTítuloCódigoCompanhia
13/05/202417:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANNXAnnexon Inc
13/05/202417:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANNXAnnexon Inc
16/04/202410:00GlobeNewswire Inc.Turnstone Biologics Appoints William Waddill to its Board of DirectorsNASDAQ:ANNXAnnexon Inc
21/02/202418:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANNXAnnexon Inc
20/02/202417:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANNXAnnexon Inc
14/02/202422:46Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ANNXAnnexon Inc
12/02/202418:24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ANNXAnnexon Inc
23/01/202419:00Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANNXAnnexon Inc
07/01/202422:00GlobeNewswire Inc.Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative DiseasesNASDAQ:ANNXAnnexon Inc
27/12/202308:30GlobeNewswire Inc.Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ANNXAnnexon Inc
22/12/202319:28Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ANNXAnnexon Inc
21/12/202318:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ANNXAnnexon Inc
20/12/202319:27GlobeNewswire Inc.Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common StockNASDAQ:ANNXAnnexon Inc
20/12/202319:24Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:ANNXAnnexon Inc
20/12/202319:10GlobeNewswire Inc.Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary EndpointNASDAQ:ANNXAnnexon Inc
20/12/202319:08GlobeNewswire Inc.Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement PathwayNASDAQ:ANNXAnnexon Inc
18/12/202318:01GlobeNewswire Inc.Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ANNXAnnexon Inc
22/11/202318:01GlobeNewswire Inc.Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:ANNXAnnexon Inc
13/11/202308:30GlobeNewswire Inc.Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial ResultsNASDAQ:ANNXAnnexon Inc
09/11/202308:30GlobeNewswire Inc.Annexon Biosciences to Participate in 2023 Jefferies London Healthcare ConferenceNASDAQ:ANNXAnnexon Inc
24/10/202307:30GlobeNewswire Inc.Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic AtrophyNASDAQ:ANNXAnnexon Inc
10/10/202307:30GlobeNewswire Inc.Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)NASDAQ:ANNXAnnexon Inc
19/09/202307:30GlobeNewswire Inc.Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare ConferenceNASDAQ:ANNXAnnexon Inc
18/09/202317:01GlobeNewswire Inc.Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ANNXAnnexon Inc
07/08/202307:30GlobeNewswire Inc.Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial ResultsNASDAQ:ANNXAnnexon Inc
02/08/202318:06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ANNXAnnexon Inc
30/07/202313:00GlobeNewswire Inc.Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic AtrophyNASDAQ:ANNXAnnexon Inc
27/07/202307:30GlobeNewswire Inc.Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical OfficerNASDAQ:ANNXAnnexon Inc
24/07/202307:30GlobeNewswire Inc.Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023NASDAQ:ANNXAnnexon Inc
22/06/202314:26Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ANNXAnnexon Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ANNX

Seu Histórico Recente

COIN
CATVILLSUST
CATVILLSCOIN
LSE
U71G
Amdi Us 7-10
BIT
F36223
Vontobel Financial Produ...
BIT
F15793
Vontobel Financial Produ...
USOTC
FSNGF
Fosun Tourism (PK)
COIN
SOFIIUST
LSE
0RDR
Nbg Pangaea Real Estate ...
ASX
CNN
Cardia Bioplastics
BIT
F17265
Vontobel Financial Produ...
NASDAQ
TPIC
TPI Composites
COIN
QUBNEUR
NYSE
QD
Qudian
USOTC
TRKNF
Turk Telekomunikasyon AS (PK)
BIBX
COSDUSDT
Chess Of Stars Dividents
COIN
LSRBTC
USOTC
CRGH
Carriage House Event Cen... (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados